G C Connolly1, M Dalal, J Lin, A A Khorana. 1. Department of Hematology and Oncology, University of Rochester, Rochester, NY 14642, USA. gregory_connolly@urmc.rochester.edu
Abstract
BACKGROUND: The incidence and economic impact of lung cancer-associated venous thromboembolic (VTE) events in a contemporary ambulatory setting is unknown. PATIENTS AND METHODS: We conducted a retrospective cohort analysis utilizing the IMS Patient-Centric database of US healthcare claims and recorded VTE events occurring 3-12 months after chemotherapy initiation. RESULTS: Lung cancer (n=6732) and control (n=17 284) cohorts had 51% women, with a mean age of 64 years. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI] 2.55, 3.89), and 1.4% of the control cohort (P<0.0001). Charlson Comorbidity Index ≥ 5 (CCI; OR, 2.56; 95% CI 1.02, 6.39; P=0.045), the use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI 1.40, 1.89; P<0.0001), and congestive heart failure (CHF; OR, 1.29; 95% CI 1.01, 1.66; P=0.045) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancer patients the average total healthcare payment was $84,187 in patients with VTE compared to $56,818 in patients without VTE (P<0.0001). CONCLUSIONS: VTE is common among lung cancer patients receiving chemotherapy and is associated with increased healthcare utilization.
BACKGROUND: The incidence and economic impact of lung cancer-associated venous thromboembolic (VTE) events in a contemporary ambulatory setting is unknown. PATIENTS AND METHODS: We conducted a retrospective cohort analysis utilizing the IMS Patient-Centric database of US healthcare claims and recorded VTE events occurring 3-12 months after chemotherapy initiation. RESULTS:Lung cancer (n=6732) and control (n=17 284) cohorts had 51% women, with a mean age of 64 years. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI] 2.55, 3.89), and 1.4% of the control cohort (P<0.0001). Charlson Comorbidity Index ≥ 5 (CCI; OR, 2.56; 95% CI 1.02, 6.39; P=0.045), the use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI 1.40, 1.89; P<0.0001), and congestive heart failure (CHF; OR, 1.29; 95% CI 1.01, 1.66; P=0.045) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancerpatients the average total healthcare payment was $84,187 in patients with VTE compared to $56,818 in patients without VTE (P<0.0001). CONCLUSIONS:VTE is common among lung cancerpatients receiving chemotherapy and is associated with increased healthcare utilization.
Authors: Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2017-12-29
Authors: Taxiarchis V Kourelis; Ewa M Wysokinska; Yi Wang; Ping Yang; Aaron S Mansfield; Alfonso J Tafur Journal: Lung Cancer Date: 2014-10-12 Impact factor: 5.705
Authors: Konstantinos Syrigos; Dimitra Grapsa; Rabiatou Sangare; Ilias Evmorfiadis; Annette K Larsen; Patrick Van Dreden; Paraskevi Boura; Andriani Charpidou; Elias Kotteas; Theodoros N Sergentanis; Ismail Elalamy; Anna Falanga; Grigoris T Gerotziafas Journal: Oncologist Date: 2018-08-13
Authors: Elie A Akl; Lara A Kahale; Maram B Hakoum; Charbel F Matar; Francesca Sperati; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Anneliese Synnot; Holger Schünemann Journal: Cochrane Database Syst Rev Date: 2017-09-11